Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew Stern

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS clinical diagnostic criteria for Parkinson's diseaseRonald B Postuma, Daniela Berg, Matthew Stern, et al.
Journal of Clinical Medicine Research|April 10, 2023
Risk Factors Associated With Atrial Fibrillation in Elderly PatientsJeeyong Shin, Megha Andrews, Lindsey DeJean, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS research criteria for prodromal Parkinson's diseaseDaniela Berg, Ronald B Postuma, Charles H Adler, et al.
JAMA|January 8, 2009
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trialFrances M Weaver, Kenneth Follett, Matthew Stern, et al.
Annals of Neurology|June 11, 2015
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trialC Warren Olanow, Raymond T Bartus, Tiffany L Baumann, et al.
The New England Journal of Medicine|June 4, 2010
Pallidal versus subthalamic deep-brain stimulation for Parkinson's diseaseKenneth A Follett, Frances M Weaver, Matthew Stern, et al.
The Lancet. Neurology|October 26, 2010
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialWilliam J Marks, Raymond T Bartus, Joao Siffert, et al.
Neurology|June 23, 2012
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomesFrances M Weaver, Kenneth A Follett, Matthew Stern, et al.
NPJ Parkinson'S Disease|May 3, 2024
Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide levelThomas F Tropea, Whitney Hartstone, Noor Amari, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Movement disorder society criteria for clinically established early Parkinson's diseaseDaniela Berg, Charles H Adler, Bastiaan R Bloem, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS clinical diagnostic criteria for Parkinson's diseaseRonald B Postuma, Daniela Berg, Matthew Stern, et al.
Journal of Clinical Medicine Research|April 10, 2023
Risk Factors Associated With Atrial Fibrillation in Elderly PatientsJeeyong Shin, Megha Andrews, Lindsey DeJean, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 17, 2015
MDS research criteria for prodromal Parkinson's diseaseDaniela Berg, Ronald B Postuma, Charles H Adler, et al.
JAMA|January 8, 2009
Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trialFrances M Weaver, Kenneth Follett, Matthew Stern, et al.
Annals of Neurology|June 11, 2015
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trialC Warren Olanow, Raymond T Bartus, Tiffany L Baumann, et al.
The New England Journal of Medicine|June 4, 2010
Pallidal versus subthalamic deep-brain stimulation for Parkinson's diseaseKenneth A Follett, Frances M Weaver, Matthew Stern, et al.
The Lancet. Neurology|October 26, 2010
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trialWilliam J Marks, Raymond T Bartus, Joao Siffert, et al.
Neurology|June 23, 2012
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomesFrances M Weaver, Kenneth A Follett, Matthew Stern, et al.
NPJ Parkinson'S Disease|May 3, 2024
Genetic and phenotypic characterization of Parkinson's disease at the clinic-wide levelThomas F Tropea, Whitney Hartstone, Noor Amari, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 27, 2018
Movement disorder society criteria for clinically established early Parkinson's diseaseDaniela Berg, Charles H Adler, Bastiaan R Bloem, et al.
Pageof 6